Enorama Pharma has entered an agreement to settle outstanding loans with its main owner, DS Global, through a directed share issue. The conversion of debt, including facilities totaling 20 million SEK, 5 million SEK, 2 million USD, and 4 million USD, will be executed at a subscription price of 0.4 SEK per share, potentially pushing DS Global's ownership above 30%.
Outstanding loans to main owner DS Global (SEK 20m, SEK 5m and USD 2m + USD 4m facilities) will be repaid via a directed settlement issue at SEK 0.4 per share, implying very large new share issuance of roughly 31m shares. Combined with the previously communicated control balance sheet (negative equity), this means heavy dilution for existing holders, which pressures the share price. The deal does avoid loan defaults and keeps the company funded, which limits an outright insolvency scenario.
- ▼ Directed settlement issue at SEK 0.4 per share agreed 13 November 2026 to repay all loans under Loan Agreements I-IV including interest
- ▼ DS Global may exceed 30% ownership through the conversion
- ▲ The agreement restores equity and avoids repayment defaults, providing continued funding from the main owner
- ▲ The conversion is framed as being in the interest of all shareholders and removes uncertainty about loan repayment